Gene therapy in renal diseases

被引:19
作者
Imai, E [1 ]
Takabatake, Y [1 ]
Mizui, M [1 ]
Isaka, Y [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Internal Med, Div Nephrol, Suita, Osaka 565, Japan
关键词
gene therapy; renal disease; glomerulonephritis;
D O I
10.1111/j.1523-1755.2004.05409.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney-targeted gene therapy could be an ideal treatment for renal diseases since the therapeutic molecule is limited in the kidney and the systemic effect may be minimized. The technical development of the gene delivery to kidney and the identification of the responsive gene for a particular disease encourage the challenge to hereditary diseases. Collagen type IV reassembling was reported to be succeeded in Alpori syndrome model by introduction of exogenous COL4A5 gene. Many gene therapies are evaluated in various glomerulonephritis models and unilateral ureteral obstruction (UUO) model, and favorable results are accumulated. Transplant kidney is an ideal target for gene therapy, by which ischemia reperfusion, acute rejection and chronic allograft nephropathy can be treated. The importation of the novel technology. for example hybrid stem cell-gene therapy could promote the gene therapy of renal diseases toward clinical application.
引用
收藏
页码:1551 / 1555
页数:5
相关论文
共 40 条
  • [1] Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis
    Akagi, Y
    Isaka, Y
    Arai, M
    Kaneko, T
    Takenaka, M
    Moriyama, T
    Kaneda, Y
    Ando, A
    Orita, Y
    Kamada, T
    Ueda, N
    Imai, E
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (01) : 148 - 155
  • [2] Azuma H, 2001, J AM SOC NEPHROL, V12, P1280, DOI 10.1681/ASN.V1261280
  • [3] Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis
    Carl, M
    Akagi, Y
    Weidner, S
    Isaka, Y
    Imai, E
    Rupprecht, HD
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (04) : 1302 - 1312
  • [4] Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney
    Choi, YK
    Kim, YJ
    Park, HS
    Choi, K
    Paik, SG
    Lee, YI
    Park, JG
    [J]. GENE THERAPY, 2003, 10 (07) : 559 - 568
  • [5] Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury
    Furuichi, K
    Wada, T
    Iwata, Y
    Kitagawa, K
    Kobayashi, K
    Hashimoto, H
    Ishiwata, Y
    Tomosugi, N
    Mukaida, N
    Matsushima, K
    Egashira, K
    Yokoyama, H
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04): : 1066 - 1071
  • [6] Gao XJ, 2002, KIDNEY INT, V62, P1238
  • [7] Application of SFHR to gene therapy of monogenic disorders
    Goncz, KK
    Prokopishyn, NL
    Chow, BL
    Davis, BR
    Gruenert, DC
    [J]. GENE THERAPY, 2002, 9 (11) : 691 - 694
  • [8] Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat
    Haller, H
    Dragun, D
    Miethke, A
    Park, JK
    Weis, A
    Lippoldt, A
    Gross, V
    Luft, FC
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (02) : 473 - 480
  • [9] Heikkila P, 1996, GENE THER, V3, P21
  • [10] Adenovirus-mediated transfer of type IV collagen α5 chain cDNA into swine kidney in vivo:: deposition of the protein into the glomerular basement membrane
    Heikkilä, P
    Tibell, A
    Morita, T
    Chen, Y
    Wu, G
    Sado, Y
    Ninomiya, Y
    Pettersson, E
    Tryggvason, K
    [J]. GENE THERAPY, 2001, 8 (11) : 882 - 890